Joshua Brody, MD, is the Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai and a faculty member of the Department of Immunology and Immunotherapy, and the Icahn Genomics Institute. Since joining Mount Sinai in 2011, he has developed a robust clinical program, as well as a translational Cancer Immunotherapy Lab which investigates basic and applied tumor immunology for the development of novel therapies, particularly for lymphomas, breast cancer, and other solid tumors with results published in top-tier journals including Nature Medicine and Cancer Discovery.  Dr. Brody has pioneered a therapeutic vaccine approach—in situ vaccination—that induces anti-tumor immunity at the tumor site and can also cause regression of tumors throughout the body. He has also developed a way to use increase the power of immunotherapy drugs against treatment-resistant lymphomas by combining them with stem cell transplantation.  Recently, his group discovered a novel approach to improve immunotherapies by preventing a common escape mechanism that tumors use to evade CAR-T and bispecific antibody therapies.

Dr. Brody’s research receives funding from numerous grantors, including the National Institutes of Health, the Department of Defense, the Cancer Research Institute, the Lymphoma Research Foundation, the Damon Runyon Cancer Research Foundation, and the Follicular Lymphoma Research Foundation. He is a member of numerous professional organizations, including the Society for the Immunotherapy of Cancer, the American Society of Hematology, the American Society of Clinical Oncology and the Alliance for Clinical Trials in Oncology.